Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune™

Abstract:
PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune™ nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development. Merck obtains the rights to utilize the technology with two investigational antigen-specific cancer immunotherapies which are in pre-clinical development.

PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune™

Lawrenceburg, IN | Posted on July 8th, 2012

Dr. Frank Bedu-Addo, Chief Executive of PDS Biotechnology Corporation said, "We are very pleased that Merck which is experienced in the clinical development of cancer immunotherapies would like to utilize the Versamune™ technology. For PDS Biotechnology Corporation, this deal is important since the company's business strategy is focused on a few strategic out-licensing or partnering deals at a preclinical or early clinical stage. This is the stage where companies will be seeking to enhance their pipelines by taking advantage of a new technology that has broad potential applications in clinical research into the treatment and prevention of cancer and infectious diseases."

####

About PDS Biotechnology Corporation
PDS Biotechnology Corporation is a privately held biotechnology company founded to exploit the newly discovered properties of specific synthetic positively charged (cationic) lipids to commercialize a new generation of immunotherapies and vaccines. The proprietary Versamune™ platform nanotechnology, when combined with specific cancer-associated molecules, has been demonstrated to lead to increased tumor regression rates compared to leading clinical adjuvants in pre-clinical cancer models (Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530). The Versamune™ nanotechnology presents a giant step forward in the development of the next generation of immunotherapies. PDS Biotechnology Corporation's lead products are being developed to treat prevalent cancers such as cervical cancer, head and neck cancer and melanoma. The technology is also being applied to the development of vaccines which are designed to protect against pandemic diseases. Visit www.pdsbiotech.com for more information on Versamune™ and products in development.

For more information, please click here

Contacts:
PDS Biotechnology Corporation
500 Industrial Drive
Suite A
Lawrenceburg, IN 47025
Tel: 812-537-0779
Fax: 812-537-1614

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanotechnology and math deliver two-in-one punch for cancer therapy resistance June 24th, 2016

Researchers discover new chemical sensing technique: Technique allows sharper detail -- and more information -- with near infrared light June 24th, 2016

GraphExeter illuminates bright new future for flexible lighting devices June 23rd, 2016

Soft decoupling of organic molecules on metal June 23rd, 2016

Nanomedicine

Nanotechnology and math deliver two-in-one punch for cancer therapy resistance June 24th, 2016

Self-assembling icosahedral protein designed: Self-assembling icosahedral protein designed June 22nd, 2016

Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016

New nanoparticle technology developed to treat aggressive thyroid cancer: Platform designed to deliver nanotherapy effective in preclinical models of metastatic anaplastic thyroid cancer June 21st, 2016

Announcements

Nanotechnology and math deliver two-in-one punch for cancer therapy resistance June 24th, 2016

Researchers discover new chemical sensing technique: Technique allows sharper detail -- and more information -- with near infrared light June 24th, 2016

GraphExeter illuminates bright new future for flexible lighting devices June 23rd, 2016

Soft decoupling of organic molecules on metal June 23rd, 2016

Patents/IP/Tech Transfer/Licensing

New 'ukidama' nanoparticle structure revealed June 14th, 2016

Rice wins award to recruit cancer researcher: $2 million CPRIT grant aims to bring MIT researcher Omid Veiseh to Houston June 7th, 2016

Nanobiotix receives US$1m milestone payment from PharmaEngine: First patient injected with NBTXR3 in soft tissue sarcoma registration phase in Asia May 31st, 2016

Programmable materials find strength in molecular repetition May 23rd, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic